The ideal scaffold for bone regeneration is required to be highly porous, non-immunogenic, biostable until the new tissue formation, bioresorbable and osteoconductive. This study aimed at investigating the process of new bone formation in patients treated with granular SmartBone(®) for sinus augmentation, providing an extensive histologic analysis. Five biopsies were collected at 4-9 months post SmartBone(®) implantation and processed for histochemistry and immunohistochemistry. Histomorphometric analysis was performed. Bone-particle conductivity index (BPCi) was used to assess SmartBone(®) osteoconductivity. At 4 months, SmartBone(®) (12%) and new bone (43.9%) were both present and surrounded by vascularized connective tissue (37.2%). New bone was grown on SmartBone(®) (BPCi=0.22). At 6 months, SmartBone(®) was almost completely resorbed (0.5%) and new bone was massively present (80.8%). At 7 and 9 months, new bone accounted for a large volume fraction (79.3% and 67.4%, respectively) and SmartBone(®) was resorbed (0.5% and 0%, respectively). Well-oriented lamellae and bone scars, typical of mature bone, were observed. In all the biopsies, bone matrix biomolecules and active osteoblasts were visible. The absence of inflammatory cells confirmed SmartBone(®) biocompatibility and non-immunogenicity. These data indicate that SmartBone(®) is osteoconductive, promotes fast bone regeneration, leading to mature bone formation in about 7 months.
Bovine bone matrix/poly(l-lactic-co-ε-caprolactone)/gelatin hybrid scaffold (SmartBone(®)) for maxillary sinus augmentation: A histologic study on bone regeneration
D'ALESSANDRO, DELFOPrimo
;Milazzo, Mario;MOSCATO, STEFANIA;DANTI, SERENA
Ultimo
2017-01-01
Abstract
The ideal scaffold for bone regeneration is required to be highly porous, non-immunogenic, biostable until the new tissue formation, bioresorbable and osteoconductive. This study aimed at investigating the process of new bone formation in patients treated with granular SmartBone(®) for sinus augmentation, providing an extensive histologic analysis. Five biopsies were collected at 4-9 months post SmartBone(®) implantation and processed for histochemistry and immunohistochemistry. Histomorphometric analysis was performed. Bone-particle conductivity index (BPCi) was used to assess SmartBone(®) osteoconductivity. At 4 months, SmartBone(®) (12%) and new bone (43.9%) were both present and surrounded by vascularized connective tissue (37.2%). New bone was grown on SmartBone(®) (BPCi=0.22). At 6 months, SmartBone(®) was almost completely resorbed (0.5%) and new bone was massively present (80.8%). At 7 and 9 months, new bone accounted for a large volume fraction (79.3% and 67.4%, respectively) and SmartBone(®) was resorbed (0.5% and 0%, respectively). Well-oriented lamellae and bone scars, typical of mature bone, were observed. In all the biopsies, bone matrix biomolecules and active osteoblasts were visible. The absence of inflammatory cells confirmed SmartBone(®) biocompatibility and non-immunogenicity. These data indicate that SmartBone(®) is osteoconductive, promotes fast bone regeneration, leading to mature bone formation in about 7 months.File | Dimensione | Formato | |
---|---|---|---|
Dalessandro_810085.pdf
Open Access dal 01/11/2017
Tipologia:
Documento in Post-print
Licenza:
Creative commons
Dimensione
1.41 MB
Formato
Adobe PDF
|
1.41 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.